Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Christopher Paul Cannon, M.D.

Co-Author

Back to Details
This page shows the publications co-authored by Christopher Cannon and Deepak Bhatt.
Christopher Cannon
Connection Strength
10.106
Deepak Bhatt
  1. Clinical trials update from the annual scientific session of the American College of Cardiology 2006. Am J Cardiol. 2006 Dec 18; 98(12A):36Q-41Q.
    View in: PubMed
    Score: 0.341
  2. Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2021 Dec; 3(5):619-634.
    View in: PubMed
    Score: 0.243
  3. Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial. EuroIntervention. 2021 Aug 27; 17(6):474-480.
    View in: PubMed
    Score: 0.239
  4. Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US. JAMA Cardiol. 2021 Jun 16.
    View in: PubMed
    Score: 0.236
  5. The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials). Clin Cardiol. 2021 Jul; 44(7):1002-1010.
    View in: PubMed
    Score: 0.235
  6. Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI. Eur Heart J Cardiovasc Pharmacother. 2020 Dec 01.
    View in: PubMed
    Score: 0.227
  7. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2021 01 14; 384(2):129-139.
    View in: PubMed
    Score: 0.226
  8. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021 01 14; 384(2):117-128.
    View in: PubMed
    Score: 0.226
  9. Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial. Circ Cardiovasc Interv. 2020 04; 13(4):e008349.
    View in: PubMed
    Score: 0.217
  10. Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. Am J Cardiol. 2020 05 15; 125(10):1577-1581.
    View in: PubMed
    Score: 0.216
  11. Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2020 01 21; 75(2):238-240.
    View in: PubMed
    Score: 0.214
  12. Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation Post-PCI: Time in Therapeutic Range. J Am Coll Cardiol. 2019 11 12; 74(19):2431-2433.
    View in: PubMed
    Score: 0.211
  13. Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States. Am Heart J. 2020 01; 219:70-77.
    View in: PubMed
    Score: 0.210
  14. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. Eur Heart J. 2019 05 14; 40(19):1553-1562.
    View in: PubMed
    Score: 0.204
  15. Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists. J Am Coll Cardiol. 2019 04 02; 73(12):1596-1598.
    View in: PubMed
    Score: 0.202
  16. Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial. Am Heart J. 2019 06; 212:13-22.
    View in: PubMed
    Score: 0.201
  17. Reply to: Dual vs. triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Eur Heart J. 2019 01 07; 40(2):218-219.
    View in: PubMed
    Score: 0.199
  18. Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling. J Am Coll Cardiol. 2018 12 25; 72(25):3370-3372.
    View in: PubMed
    Score: 0.198
  19. Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J. 2018 05 14; 39(19):1726-1735a.
    View in: PubMed
    Score: 0.190
  20. Quality Improvement in Management of Acute Coronary Syndrome: Continuing Medical Education and Peer Coaching Improve Antiplatelet Medication Adherence and Reduce Hospital Readmissions. Crit Pathw Cardiol. 2017 09; 16(3):96-101.
    View in: PubMed
    Score: 0.181
  21. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017 10 19; 377(16):1513-1524.
    View in: PubMed
    Score: 0.181
  22. Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. Clin Cardiol. 2016 Oct; 39(10):555-564.
    View in: PubMed
    Score: 0.169
  23. Relation Between Hospital Length of Stay and Quality of Care in Patients With Acute Coronary Syndromes (from the American Heart Association's Get With the Guidelines--Coronary Artery Disease Data Set). Am J Cardiol. 2016 Jan 15; 117(2):201-5.
    View in: PubMed
    Score: 0.160
  24. The effects of proton pump inhibition on patient-reported severity of dyspepsia when receiving dual anti-platelet therapy with clopidogrel and low-dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial. Aliment Pharmacol Ther. 2015 Aug; 42(3):365-74.
    View in: PubMed
    Score: 0.155
  25. Response to Relationship of race/ethnicity with door-to-balloon time and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: Findings from Get With the Guidelines-Coronary Artery Diseases. Authors' reply. Clin Cardiol. 2014 May; 37(5):323.
    View in: PubMed
    Score: 0.142
  26. Use of renin-angiotensin system blockers in acute coronary syndromes: findings from Get With the Guidelines-Coronary Artery Disease Program. Circ Cardiovasc Qual Outcomes. 2014 Mar; 7(2):227-35.
    View in: PubMed
    Score: 0.142
  27. Evolving antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: results from a survey among US cardiologists. Clin Cardiol. 2014 Feb; 37(2):103-7.
    View in: PubMed
    Score: 0.141
  28. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA. 2013 Oct 23; 310(16):1711-20.
    View in: PubMed
    Score: 0.139
  29. Relationship of race/ethnicity with door-to-balloon time and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: findings from Get With the Guidelines-Coronary Artery Disease. Clin Cardiol. 2013 Dec; 36(12):749-56.
    View in: PubMed
    Score: 0.138
  30. Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction. J Am Coll Cardiol. 2013 Jan 08; 61(1):35-40.
    View in: PubMed
    Score: 0.130
  31. Trends in smoking cessation counseling: experience from American Heart Association-get with the guidelines. Clin Cardiol. 2012; 35(7):396-403.
    View in: PubMed
    Score: 0.122
  32. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010 Nov 11; 363(20):1909-17.
    View in: PubMed
    Score: 0.112
  33. Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). Am J Cardiol. 2010 Feb 15; 105(4):445-52.
    View in: PubMed
    Score: 0.107
  34. Quality of care for acute coronary syndrome patients with known atherosclerotic disease: results from the Get With the Guidelines Program. Circulation. 2009 Aug 18; 120(7):560-7.
    View in: PubMed
    Score: 0.103
  35. Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J. 2009 May; 30(10):1195-202.
    View in: PubMed
    Score: 0.101
  36. Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. Am Heart J. 2008 Oct; 156(4):719-27.
    View in: PubMed
    Score: 0.096
  37. An annual, prospective, international study of outpatients with cardiovascular disease or risk factors: design and methods of the CardioMonitor registry. Crit Pathw Cardiol. 2007 Jun; 6(2):72-5.
    View in: PubMed
    Score: 0.089
  38. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA. 2004 Nov 03; 292(17):2096-104.
    View in: PubMed
    Score: 0.074
  39. A novel risk score to identify the need for triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a post hoc analysis of the RE-DUAL PCI trial. EuroIntervention. 2022 Feb 02.
    View in: PubMed
    Score: 0.062
  40. What Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD Registry. J Am Heart Assoc. 2021 08 17; 10(16):e020893.
    View in: PubMed
    Score: 0.059
  41. Association of Socioeconomic Disadvantage With Long-term Mortality After Myocardial Infarction: The Mass General Brigham YOUNG-MI Registry. JAMA Cardiol. 2021 08 01; 6(8):880-888.
    View in: PubMed
    Score: 0.059
  42. Atherosclerotic cardiovascular disease risk and elevated lipoprotein(a) among young adults with myocardial infarction: The Partners YOUNG-MI Registry. Eur J Prev Cardiol. 2021 07 23; 28(8):e12-e14.
    View in: PubMed
    Score: 0.059
  43. Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial. Ann Intern Med. 2021 08; 174(8):1065-1072.
    View in: PubMed
    Score: 0.059
  44. Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial. JACC Cardiovasc Interv. 2021 04 12; 14(7):768-780.
    View in: PubMed
    Score: 0.058
  45. Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. Circulation. 2021 02 16; 143(7):685-695.
    View in: PubMed
    Score: 0.058
  46. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update. Circulation. 2021 02 09; 143(6):583-596.
    View in: PubMed
    Score: 0.057
  47. Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial. JAMA. 2021 01 05; 325(1):39-49.
    View in: PubMed
    Score: 0.057
  48. 2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021 02 09; 77(5):629-658.
    View in: PubMed
    Score: 0.057
  49. Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation. 2021 02 02; 143(5):470-478.
    View in: PubMed
    Score: 0.057
  50. Study of lipoprotein(a) and its impact on atherosclerotic cardiovascular disease: Design and rationale of the Mass General Brigham Lp(a) Registry. Clin Cardiol. 2020 Nov; 43(11):1209-1215.
    View in: PubMed
    Score: 0.056
  51. Safety and efficacy of drug eluting stents vs bare metal stents in patients with atrial fibrillation: A systematic review and meta-analysis. Thromb Res. 2020 11; 195:128-135.
    View in: PubMed
    Score: 0.055
  52. Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial. Drugs. 2020 Jul; 80(10):995-1005.
    View in: PubMed
    Score: 0.055
  53. Atherosclerotic cardiovascular disease risk and elevated lipoprotein(a) among young adults with myocardial infarction: The Partners YOUNG-MI Registry. Eur J Prev Cardiol. 2020 Jun 23.
    View in: PubMed
    Score: 0.055
  54. Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI. Am J Med. 2020 11; 133(11):1302-1312.
    View in: PubMed
    Score: 0.055
  55. Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis. JAMA Cardiol. 2020 05 01; 5(5):582-589.
    View in: PubMed
    Score: 0.054
  56. No Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials. JACC Cardiovasc Interv. 2020 04 27; 13(8):1012-1014.
    View in: PubMed
    Score: 0.054
  57. Adherence to Guideline Medication Recommendations to Prevent Atherosclerotic Cardiovascular Disease Progression Among Adults With Prior Myocardial Infarction. JAMA Netw Open. 2020 04 01; 3(4):e203032.
    View in: PubMed
    Score: 0.054
  58. Reply: Our Perspective on Anticoagulation Therapy Post-PCI in Atrial Fibrillation Patients With Diabetes. JACC Cardiovasc Interv. 2020 03 09; 13(5):658-659.
    View in: PubMed
    Score: 0.054
  59. Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis. JACC Cardiovasc Interv. 2019 12 09; 12(23):2331-2341.
    View in: PubMed
    Score: 0.053
  60. Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes. JACC Cardiovasc Interv. 2019 12 09; 12(23):2346-2355.
    View in: PubMed
    Score: 0.053
  61. Comparison of the Effect of Age (< 75 Versus = 75) on the Efficacy and Safety of Dual Therapy (Dabigatran?+?Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin?+?Aspirin?+?Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial). Am J Cardiol. 2020 03 01; 125(5):735-743.
    View in: PubMed
    Score: 0.053
  62. Diabetes Is Associated With Worse Long-term Outcomes in Young Adults After Myocardial Infarction: The Partners YOUNG-MI Registry. Diabetes Care. 2020 08; 43(8):1843-1850.
    View in: PubMed
    Score: 0.052
  63. Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI. JACC Cardiovasc Interv. 2019 08 26; 12(16):1553-1561.
    View in: PubMed
    Score: 0.052
  64. Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials. JAMA Cardiol. 2019 08 01; 4(8):747-755.
    View in: PubMed
    Score: 0.052
  65. Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 07 09; 74(1):83-99.
    View in: PubMed
    Score: 0.051
  66. Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease. Circulation. 2019 08 13; 140(7):618-620.
    View in: PubMed
    Score: 0.051
  67. Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction. J Am Coll Cardiol. 2019 05 21; 73(19):2439-2450.
    View in: PubMed
    Score: 0.051
  68. Modes and timing of death in 66?252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. Eur Heart J. 2018 11 07; 39(42):3810-3820.
    View in: PubMed
    Score: 0.049
  69. WITHDRAWN: Raising the Bar by Lowering the Target: Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management. Am J Cardiol. 2018 Aug 16.
    View in: PubMed
    Score: 0.048
  70. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update. Circulation. 2018 07 31; 138(5):527-536.
    View in: PubMed
    Score: 0.048
  71. High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial. Am Heart J. 2018 08; 202:97-103.
    View in: PubMed
    Score: 0.048
  72. Sustained sex-based treatment differences in acute coronary syndrome care: Insights from the American Heart Association Get With The Guidelines Coronary Artery Disease Registry. Clin Cardiol. 2018 Jun; 41(6):758-768.
    View in: PubMed
    Score: 0.048
  73. Cardiovascular Risk and Statin Eligibility of Young Adults After an MI: Partners YOUNG-MI Registry. J Am Coll Cardiol. 2018 01 23; 71(3):292-302.
    View in: PubMed
    Score: 0.046
  74. Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events. Clin Cardiol. 2017 Oct; 40(10):932-939.
    View in: PubMed
    Score: 0.045
  75. Compliance with guideline-directed therapy in diabetic patients admitted with acute coronary syndrome: Findings from the American Heart Association's Get With The Guidelines-Coronary Artery Disease (GWTG-CAD) program. Am Heart J. 2017 May; 187:78-87.
    View in: PubMed
    Score: 0.044
  76. Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update. Circ Cardiovasc Interv. 2016 11; 9(11).
    View in: PubMed
    Score: 0.043
  77. Reply: High Risk of Gastrointestinal Bleeding on Dual Antiplatelet Treatment. J Am Coll Cardiol. 2016 08 30; 68(9):981-2.
    View in: PubMed
    Score: 0.042
  78. Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial. Am J Med. 2016 Sep; 129(9):1002-5.
    View in: PubMed
    Score: 0.041
  79. Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. J Am Coll Cardiol. 2016 Apr 12; 67(14):1661-71.
    View in: PubMed
    Score: 0.041
  80. Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease. Am J Med. 2015 Apr; 128(4):426.e1-9.
    View in: PubMed
    Score: 0.037
  81. Targeted versus standard feedback: results from a randomized quality improvement trial. Am Heart J. 2015 Jan; 169(1):132-41.e2.
    View in: PubMed
    Score: 0.037
  82. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J. 2014 Nov 01; 35(41):2864-72.
    View in: PubMed
    Score: 0.036
  83. Quality of care for patients with acute coronary syndromes as a function of hospital revascularization capability: Insights from get with the guidelines-CAD. Clin Cardiol. 2014 May; 37(5):285-92.
    View in: PubMed
    Score: 0.035
  84. NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease. Am J Med. 2014 Jan; 127(1):53-60.e1.
    View in: PubMed
    Score: 0.035
  85. Synthesizing lessons learned from get with the guidelines: the value of disease-based registries in improving quality and outcomes. Circulation. 2013 Nov 26; 128(22):2447-60.
    View in: PubMed
    Score: 0.035
  86. Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH Registry. Clin Cardiol. 2013 Dec; 36(12):721-7.
    View in: PubMed
    Score: 0.035
  87. Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis. Am J Med. 2013 Aug; 126(8):693-700.e1.
    View in: PubMed
    Score: 0.034
  88. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J. 2013 Apr; 34(16):1204-14.
    View in: PubMed
    Score: 0.032
  89. ß-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012 Oct 03; 308(13):1340-9.
    View in: PubMed
    Score: 0.032
  90. Guideline adherence after ST-segment elevation versus non-ST segment elevation myocardial infarction. Circ Cardiovasc Qual Outcomes. 2012 Sep 01; 5(5):654-61.
    View in: PubMed
    Score: 0.032
  91. Trends in clinical, demographic, and biochemical characteristics of patients with acute myocardial infarction from 2003 to 2008: a report from the american heart association get with the guidelines coronary artery disease program. J Am Heart Assoc. 2012 Aug; 1(4):e001206.
    View in: PubMed
    Score: 0.032
  92. Predictors of adherence to performance measures in patients with acute myocardial infarction. Am J Med. 2013 Jan; 126(1):74.e1-9.
    View in: PubMed
    Score: 0.032
  93. Quality of care and outcomes among patients with acute myocardial infarction by level of kidney function at admission: report from the get with the guidelines coronary artery disease program. Clin Cardiol. 2012 Sep; 35(9):541-7.
    View in: PubMed
    Score: 0.032
  94. Reperfusion strategies and quality of care in 5339 patients age 80 years or older presenting with ST-elevation myocardial infarction: analysis from get with the guidelines-coronary artery disease. Clin Cardiol. 2012 Oct; 35(10):632-40.
    View in: PubMed
    Score: 0.032
  95. Age and gender differences in quality of care and outcomes for patients with ST-segment elevation myocardial infarction. Am J Med. 2012 Oct; 125(10):1000-9.
    View in: PubMed
    Score: 0.032
  96. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012 Jul 03; 126(1):65-75.
    View in: PubMed
    Score: 0.031
  97. Care and outcomes of Asian-American acute myocardial infarction patients: findings from the American Heart Association Get With The Guidelines-Coronary Artery Disease program. Circ Cardiovasc Qual Outcomes. 2012 Jan; 5(1):126-33.
    View in: PubMed
    Score: 0.031
  98. Changes in myocardial infarction guideline adherence as a function of patient risk: an end to paradoxical care? J Am Coll Cardiol. 2011 Oct 18; 58(17):1760-5.
    View in: PubMed
    Score: 0.030
  99. Comparison of composite measure methodologies for rewarding quality of care: an analysis from the American Heart Association's Get With The Guidelines program. Circ Cardiovasc Qual Outcomes. 2011 Nov 01; 4(6):610-8.
    View in: PubMed
    Score: 0.030
  100. Ethnic differences in cardiovascular risks and mortality in atherothrombotic disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) registry. Mayo Clin Proc. 2011 Oct; 86(10):960-7.
    View in: PubMed
    Score: 0.030
  101. Quality of acute myocardial infarction care and outcomes in 33,997 patients aged 80 years or older: findings from Get With The Guidelines-Coronary Artery Disease (GWTG-CAD). Am Heart J. 2011 Aug; 162(2):283-290.e2.
    View in: PubMed
    Score: 0.030
  102. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospita participating in Get With The Guidelines (GWTG). Am Heart J. 2011 Feb; 161(2):418-424.e1-3.
    View in: PubMed
    Score: 0.029
  103. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). Am Heart J. 2010 Dec; 160(6):1130-6, 1136.e1-3.
    View in: PubMed
    Score: 0.028
  104. Prior cardiovascular interventions are not associated with worsened clinical outcomes in patients with symptomatic atherothrombosis. Crit Pathw Cardiol. 2010 Sep; 9(3):116-25.
    View in: PubMed
    Score: 0.028
  105. Late outcomes after carotid artery stenting versus carotid endarterectomy: insights from a propensity-matched analysis of the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation. 2010 Sep 14; 122(11):1091-100.
    View in: PubMed
    Score: 0.028
  106. Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: insights from the reduction of atherothrombosis for continued health (REACH) registry. Am Heart J. 2009 Dec; 158(6):1038-45.
    View in: PubMed
    Score: 0.026
  107. Association of hospital primary angioplasty volume in ST-segment elevation myocardial infarction with quality and outcomes. JAMA. 2009 Nov 25; 302(20):2207-13.
    View in: PubMed
    Score: 0.026
  108. The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J Am Coll Cardiol. 2009 Nov 17; 54(21):1935-45.
    View in: PubMed
    Score: 0.026
  109. Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes. Am J Cardiol. 2009 Nov 01; 104(9):1171-8.
    View in: PubMed
    Score: 0.026
  110. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry. Crit Pathw Cardiol. 2009 Sep; 8(3):104-11.
    View in: PubMed
    Score: 0.026
  111. Cardiovascular ischemic event rates in outpatients with symptomatic atherothrombosis or risk factors in the united states: insights from the REACH Registry. Crit Pathw Cardiol. 2009 Jun; 8(2):91-7.
    View in: PubMed
    Score: 0.026
  112. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA. 2008 Apr 02; 299(13):1547-60.
    View in: PubMed
    Score: 0.024
  113. Antiplatelet therapy and platelet function testing. Introduction. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I1.
    View in: PubMed
    Score: 0.023
  114. Assessing the current role of platelet function testing. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I10-6.
    View in: PubMed
    Score: 0.023
  115. The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I17-20.
    View in: PubMed
    Score: 0.023
  116. Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I2-9.
    View in: PubMed
    Score: 0.023
  117. Investigating the mechanisms of hyporesponse to antiplatelet approaches. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I21-7.
    View in: PubMed
    Score: 0.023
  118. Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I28-35.
    View in: PubMed
    Score: 0.023
  119. Antiplatelet therapy and platelet function testing. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I36.
    View in: PubMed
    Score: 0.023
  120. Comparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry). Am J Cardiol. 2007 May 01; 99(9):1212-5.
    View in: PubMed
    Score: 0.022
  121. Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE). Am J Cardiol. 2006 Nov 01; 98(9):1172-6.
    View in: PubMed
    Score: 0.021
  122. Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. Arch Intern Med. 2006 Apr 10; 166(7):806-11.
    View in: PubMed
    Score: 0.021
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.